MX392532B - Glicoproteinas recombinantes y sus usos. - Google Patents
Glicoproteinas recombinantes y sus usos.Info
- Publication number
- MX392532B MX392532B MX2016005321A MX2016005321A MX392532B MX 392532 B MX392532 B MX 392532B MX 2016005321 A MX2016005321 A MX 2016005321A MX 2016005321 A MX2016005321 A MX 2016005321A MX 392532 B MX392532 B MX 392532B
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant
- galactosidase
- methods
- glycoproteins
- recombinant glycoproteins
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title abstract 5
- 108090000288 Glycoproteins Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70592—CD52
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894879P | 2013-10-23 | 2013-10-23 | |
| US201361901942P | 2013-11-08 | 2013-11-08 | |
| PCT/US2014/061789 WO2015061464A2 (en) | 2013-10-23 | 2014-10-22 | Recombinant glycoproteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016005321A MX2016005321A (es) | 2017-01-05 |
| MX392532B true MX392532B (es) | 2025-03-24 |
Family
ID=51871299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016005321A MX392532B (es) | 2013-10-23 | 2014-10-22 | Glicoproteinas recombinantes y sus usos. |
Country Status (33)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| JP7114485B2 (ja) * | 2016-05-18 | 2022-08-08 | モデルナティエックス インコーポレイテッド | ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド |
| KR102712926B1 (ko) | 2016-10-20 | 2024-10-07 | 상가모 테라퓨틱스, 인코포레이티드 | 파브리병의 치료를 위한 방법 및 조성물 |
| US11357834B2 (en) | 2017-01-10 | 2022-06-14 | Amicus Therapeutics, Inc. | Recombinant α-galactosidase A for treatment of Fabry disease |
| CN113423419A (zh) | 2019-01-04 | 2021-09-21 | 桑格摩生物治疗股份有限公司 | 用于治疗法布里病的方法和组合物 |
| WO2025092951A1 (en) * | 2023-11-03 | 2025-05-08 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating fabry disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5356804A (en) * | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| NZ506214A (en) * | 1996-09-13 | 2002-11-26 | Transkaryotic Therapies Inc | Therapy for alpha-galactosidase A deficiency |
| EP1027069B1 (en) | 1997-10-29 | 2006-07-26 | Genzyme Corporation | Gene therapy for gaucher disease |
| US20020081654A1 (en) * | 2000-04-07 | 2002-06-27 | Sandrin Mauro Sergio | Targeting hydrolase enzymes |
| US7138262B1 (en) * | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7133354B2 (en) | 2002-08-26 | 2006-11-07 | Qualcomm Incorporated | Synchronization techniques for a wireless system |
| TWI328614B (en) * | 2002-12-23 | 2010-08-11 | Bristol Myers Squibb Co | Product quality enhancement in mammalian cell culture processes for protein production |
| CN100522988C (zh) * | 2003-04-09 | 2009-08-05 | 诺和诺德公司 | 糖peg化方法及由该方法生产的蛋白质/肽 |
| JP5967861B2 (ja) * | 2007-04-03 | 2016-08-10 | オキシレイン ユーケー リミテッド | 分子のグリコシル化 |
| US20110117601A1 (en) * | 2007-08-31 | 2011-05-19 | Markus Haberger | Glycosylation Profile Analysis |
| US9034341B2 (en) * | 2009-04-20 | 2015-05-19 | Transtech Pharma, Llc | Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions |
| DK2865751T3 (en) * | 2010-03-02 | 2017-01-09 | Protalix Ltd | Stabilized alpha-galactosidase and uses thereof |
| US20120178105A1 (en) | 2011-01-10 | 2012-07-12 | Genzyme Corporation | Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich |
| EP2665814B1 (en) * | 2011-01-20 | 2017-05-17 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
| WO2013055888A2 (en) * | 2011-10-12 | 2013-04-18 | Synageva Biopharma Corp. | Recombinant human naglu protein and uses thereof |
| EP2620506A1 (en) | 2012-01-25 | 2013-07-31 | Arla Foods Amba | Method of producing a galacto-oligosaccharide-containing composition |
| TWI528785B (zh) | 2013-02-08 | 2016-04-01 | 瑞昱半導體股份有限公司 | 立體影像的調整裝置及其方法 |
| AU2014226126B2 (en) | 2013-03-08 | 2019-02-14 | Genzyme Corporation | Continuous purification of therapeutic proteins |
-
2014
- 2014-10-21 TW TW107130267A patent/TWI793159B/zh active
- 2014-10-21 TW TW111139854A patent/TW202332774A/zh unknown
- 2014-10-21 TW TW103136272A patent/TWI642782B/zh active
- 2014-10-22 PL PL14796346T patent/PL3060660T3/pl unknown
- 2014-10-22 MX MX2016005321A patent/MX392532B/es unknown
- 2014-10-22 HR HRP20211197TT patent/HRP20211197T1/hr unknown
- 2014-10-22 EA EA201690826A patent/EA034515B1/ru not_active IP Right Cessation
- 2014-10-22 UA UAA201605455A patent/UA119857C2/uk unknown
- 2014-10-22 EP EP14796346.6A patent/EP3060660B1/en active Active
- 2014-10-22 WO PCT/US2014/061789 patent/WO2015061464A2/en not_active Ceased
- 2014-10-22 MY MYPI2019005029A patent/MY197247A/en unknown
- 2014-10-22 TN TN2016000140A patent/TN2016000140A1/en unknown
- 2014-10-22 SI SI201431857T patent/SI3060660T1/sl unknown
- 2014-10-22 DK DK14796346.6T patent/DK3060660T3/da active
- 2014-10-22 SG SG11201602932WA patent/SG11201602932WA/en unknown
- 2014-10-22 CN CN202110161563.9A patent/CN112852784A/zh active Pending
- 2014-10-22 PE PE2016000543A patent/PE20160723A1/es unknown
- 2014-10-22 CN CN201480070424.3A patent/CN105916984A/zh active Pending
- 2014-10-22 BR BR112016008086A patent/BR112016008086A2/pt not_active Application Discontinuation
- 2014-10-22 CA CA2927852A patent/CA2927852A1/en active Pending
- 2014-10-22 SG SG10201803366PA patent/SG10201803366PA/en unknown
- 2014-10-22 LT LTEPPCT/US2014/061789T patent/LT3060660T/lt unknown
- 2014-10-22 PH PH1/2016/500708A patent/PH12016500708B1/en unknown
- 2014-10-22 EP EP20183936.2A patent/EP3778884A1/en not_active Withdrawn
- 2014-10-22 ES ES14796346T patent/ES2882562T3/es active Active
- 2014-10-22 KR KR1020167013333A patent/KR102298080B1/ko active Active
- 2014-10-22 US US15/030,555 patent/US11208644B2/en active Active
- 2014-10-22 KR KR1020217027690A patent/KR102479886B1/ko active Active
- 2014-10-22 HU HUE14796346A patent/HUE055236T2/hu unknown
- 2014-10-22 JP JP2016526026A patent/JP6837334B2/ja active Active
- 2014-10-22 MY MYPI2016700943A patent/MY178632A/en unknown
- 2014-10-22 NZ NZ720384A patent/NZ720384A/en unknown
- 2014-10-22 CN CN202210146800.9A patent/CN114606217A/zh active Pending
- 2014-10-22 RS RS20210960A patent/RS62171B1/sr unknown
- 2014-10-22 PT PT147963466T patent/PT3060660T/pt unknown
- 2014-10-22 AU AU2014340152A patent/AU2014340152A1/en not_active Abandoned
- 2014-10-23 UY UY0001035794A patent/UY35794A/es not_active Application Discontinuation
-
2016
- 2016-04-11 DO DO2016000079A patent/DOP2016000079A/es unknown
- 2016-04-21 IL IL245255A patent/IL245255B/en active IP Right Grant
- 2016-04-21 CL CL2016000961A patent/CL2016000961A1/es unknown
- 2016-05-17 CR CR20160225A patent/CR20160225A/es unknown
-
2020
- 2020-01-17 JP JP2020005541A patent/JP7296327B2/ja active Active
- 2020-02-11 IL IL272609A patent/IL272609B/en unknown
- 2020-12-21 AU AU2020294173A patent/AU2020294173A1/en not_active Abandoned
-
2021
- 2021-09-22 US US17/482,193 patent/US20220064617A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202201361B (en) | Methods and compositions comprising purified recombinant polypeptides | |
| CY1125057T1 (el) | Anti-cd277 αντισωματα και χρησεις αυτων | |
| MX2025003310A (es) | Integracion dirigida de acidos nucleicos | |
| MX2023001878A (es) | Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t. | |
| PH12016500708B1 (en) | Recombinant glycoproteins and uses thereof | |
| MY186864A (en) | Fusion immunomodulatory proteins and methods for making same | |
| EA202090931A2 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
| ECSP12011803A (es) | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas | |
| PH12014502537A1 (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
| BR112016009402A2 (pt) | Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual | |
| BR112014012460A2 (pt) | proteínas recombinantes e seus usos terapêuticos | |
| BR112019000837A2 (pt) | células miméticas de célula b | |
| MX2018002921A (es) | Composicion de hormona foliculo-estimulante mamifera con estabilidad incrementada. | |
| PH12015502037A1 (en) | Activating adiponectin by casein hydrolysate | |
| WO2013109190A3 (en) | Cho-gmt recombinant protein expression | |
| WO2015003811A8 (en) | Methods for producing sialylated therapeutic proteins | |
| MX2016010680A (es) | Perfeccionamiento de expresión de proteína recombinante con el uso de un sistema de retención de célula basado en membrana. | |
| EA201992746A2 (ru) | Рекомбинантные гликопротеиды и их применения | |
| AR098154A1 (es) | Glicoproteínas recombinantes y sus usos | |
| WO2014169254A3 (en) | Therapeutic peptide-expressing cells | |
| BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos |